US Stock MarketDetailed Quotes
AUTL Autolus Therapeutics
- 3.270
- +0.175+5.65%
Close Nov 27 16:00 ET
- 3.301
- +0.031+0.94%
Post 19:58 ET
870.22MMarket Cap-2680P/E (TTM)
3.390High3.130Low1.61MVolume3.130Open3.095Pre Close5.29MTurnover1.20%Turnover RatioLossP/E (Static)266.12MShares7.45052wk High1.82P/B439.48MFloat Cap2.69052wk Low--Dividend TTM134.40MShs Float53.240Historical High--Div YieldTTM8.40%Amplitude1.600Historical Low3.284Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Autolus Therapeutics Stock Forum
ya I'm getting in here
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...
Abeona Therapeutics ( $Abeona Therapeutics (ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals (RCKT.US)$ ) ...
No comment yet